Sagimet Biosciences Inc. (SGMT)
- Previous Close
3.9200 - Open
4.0000 - Bid 4.0100 x 100
- Ask 4.1100 x 100
- Day's Range
3.8800 - 4.1500 - 52 Week Range
2.1300 - 20.7100 - Volume
325,272 - Avg. Volume
1,054,663 - Market Cap (intraday)
129.57M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
42.00
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
www.sagimet.comRecent News: SGMT
Performance Overview: SGMT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SGMT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SGMT
Valuation Measures
Market Cap
129.57M
Enterprise Value
34.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
46.48
Price/Book (mrq)
1.42
Enterprise Value/Revenue
17.37
Enterprise Value/EBITDA
-1.13
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.61%
Return on Equity (ttm)
-46.96%
Revenue (ttm)
2M
Net Income Avi to Common (ttm)
-27.88M
Diluted EPS (ttm)
-2.6600
Balance Sheet and Cash Flow
Total Cash (mrq)
94.9M
Total Debt/Equity (mrq)
0.07%
Levered Free Cash Flow (ttm)
-15.08M